SCL Group is partnering with Indonesia’s national hospital to spearhead the expansion of K-healthcare into Southeast Asia. The company is expected to accelerate the expansion of precision diagnosis–focused businesses in conjunction with local health screening infrastructure.

SCL Group announced on the 23rd that it plans to sign a memorandum of understanding (MOU) with RSCM Hospital, a national hospital under the Indonesian Ministry of Health. The hospital is a leading national medical institution in Indonesia that treats more than 1 million patients annually, and the signing ceremony will be held in Jakarta on the 27th.

Through this agreement, the two parties plan to pursue cooperation in areas including precision diagnosis such as multi-cancer early screening and genetic testing, AI-based early diagnosis solutions, joint use of medical equipment such as MRI and CT, and healthcare and IT platforms.

● Export of K-screening model…Utilization of local infrastructure is key variable

SCL Group has already established a local subsidiary, “SCL Hanaro Indonesia (SHI),” in July 2025 and has been building its business foundation by operating the “K-LAB” screening center through Hanaro Healthcare Foundation. K-LAB provides Korean-style health screening services based on its own diagnostic laboratory and advanced equipment.

With this agreement enabling the use of national hospital infrastructure, the business model that combines local screening services with precision diagnosis is expected to take a more concrete shape.

● Focus on early cancer diagnosis ‘Cancerfind’…Potential for service expansion

Early cancer diagnosis solutions lie at the core of the cooperation. An SCL official said, “The priority is cooperation in Korean-style medical services and diagnostics, and in particular, there are high local expectations for early cancer diagnosis using ‘Cancerfind.’”

There are strong local expectations for early cancer diagnosis using “Cancerfind.” The industry is watching whether this cooperation will go beyond technology exchange and lead to the operation of actual screening services.

● Targeting the Southeast Asian medical market…“Securing a key hub”

Indonesia, which has the largest population in Southeast Asia, is seen as a market with strong growth potential in preventive medicine and precision diagnosis amid rising medical demand. There is also growing momentum for bilateral healthcare cooperation following the recent visit to Korea by the Indonesian president.

SCL Group Chairman Lee Kyung-ryul said, “Indonesia is a key hub for entering the Southeast Asian medical market,” adding, “We will strengthen cooperation with local medical institutions based on our diagnostic testing and health screening capabilities and continue to spread the K-healthcare model.”

SCL Group is expanding its global presence through its affiliates, including Seoul Clinical Laboratories (SCL), Hanaro Healthcare Foundation, and SCL Healthcare, while reinforcing its data-driven precision medicine business.

Popular News